The Transporter (2022)

[Coleman John]

Thesite is secure.

The ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Background: Large trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of adverse kidney and cardiovascular outcomes in patients with heart failure or chronic kidney disease, or with type 2 diabetes and high risk of atherosclerotic cardiovascular disease. None of the trials recruiting patients with and without diabetes were designed to assess outcomes separately in patients without diabetes.

Findings: We identified 13 trials involving 90 413 participants. After exclusion of four participants with uncertain diabetes status, we analysed 90 409 participants (74 804 [827%] participants with diabetes [>99% with type 2 diabetes] and 15 605 [173%] without diabetes; trial-level mean baseline eGFR range 37-85 mL/min per 173 m2). Compared with placebo, allocation to an SGLT2 inhibitor reduced the risk of kidney disease progression by 37% (relative risk [RR] 063, 95% CI 058-069) with similar RRs in patients with and without diabetes. In the four chronic kidney disease trials, RRs were similar irrespective of primary kidney diagnosis. SGLT2 inhibitors reduced the risk of acute kidney injury by 23% (077, 070-084) and the risk of cardiovascular death or hospitalisation for heart failure by 23% (077, 074-081), again with similar effects in those with and without diabetes. SGLT2 inhibitors also reduced the risk of cardiovascular death (086, 081-092) but did not significantly reduce the risk of non-cardiovascular death (094, 088-102). For these mortality outcomes, RRs were similar in patients with and without diabetes. For all outcomes, results were broadly similar irrespective of trial mean baseline eGFR. Based on estimates of absolute effects, the absolute benefits of SGLT2 inhibition outweighed any serious hazards of ketoacidosis or amputation.

Interpretation: In addition to the established cardiovascular benefits of SGLT2 inhibitors, the randomised data support their use for modifying risk of kidney disease progression and acute kidney injury, not only in patients with type 2 diabetes at high cardiovascular risk, but also in patients with chronic kidney disease or heart failure irrespective of diabetes status, primary kidney disease, or kidney function.

This is the 2022 Transporter Application Questions and Answers (Q&A), which is a compilation of previous questions and answers relating to the 2020 Transporter Application that are also relevant to the 2022 Application. If any discrepancy exists between this Q&A and other documents provided by the Department regarding the 2020 application, the information in this document is controlling. The Application can be found here.

Additional questions may be submitted to: AGR.Ad...@illinois.gov. Please put "2022 Transporter Application Question" in the subject line. Questions must be received no later than 12:00pm on April 3 to be answered.

At its discretion, the Department may add additional information to this Q&A page based on questions it receives from applicants. The Department will not (1) add questions if they are already contained in this Q&A; (2) post questions that are fact or case specific to certain applicants; or (3) respond to questions via email.

All submitted materials should be readable and in a pdf format. Single or double-spaced materials are permitted. Applicants should follow application instructions and exhibit descriptions regarding page limits and file types.

No. When completing the application, applicants should not cross-reference sections and exhibits. Each section and exhibit should "stand alone" and contain all information the applicant desires to submit.

If you reside outside of Illinois and are unable to have your fingerprints taken by an Illinois licensed fingerprint vendor, you may have your fingerprints taken by an out-of-state agency or vendor such as a local police department. Once the fingerprints have been taken, you will need to mail them to an Illinois licensed vendor to be scanned. If you intend to have your fingerprints taken by an out-of-state agency or vendor, please follow the steps below:

There are 21 adult use cultivation centers. 40 craft grower licenses and 32 infuser licenses have been issued; not all of those are operational at this time. A list of all craft grower, infuser, and transporter licensees is available at this link. A list of adult use cultivation centers is available at this link. The Department may issue up to 60 additional craft grow licenses later this year; the Department is currently prohibited by court order from issuing those licenses. See the December 21, 2021 License Award update posted on the Adult Use Cannabis webpage for more information.

That Exhibit is not part of the 2022 application and should not be included. Any Exhibit that was included in the 2020 application that is not part of the 2022 application should not be included with the 2022 application submission.

No. Transporters are not permitted to deliver cannabis or cannabis-infused products to retail customers. As prescribed by 8 Ill. Adm. Code 1300.500(c) and 410 ILCS 705/40-25(b), a transporter may not transport cannabis or cannabis-infused products to any person other than a cultivation center, a craft grower, an infuser, a dispensing organization, a testing facility, or as otherwise authorized by rule.

Applicants are not expressly required to own their vehicles at the time of application. However, applicants are required to submit the number and type (make, year, and model) of equipment the transporter intends to use to transport cannabis and cannabis-infused products.

Cannabis must be transported in a cannabis container, as defined in the Act. All transportation activities must be conducted in a safe manner in compliance with the Act, the administrative rules, and any other applicable statutes.

No. The Cannabis Regulation and Tax Act only made offenses committed in Illinois eligible to be expunged. As such, offenses committed in other states cannot be used to qualify an applicant as a Social Equity Applicant.

Examples of records could include, but are not limited to, income tax forms, court records, insurance forms, bank statements, pension payments, records from public assistance agencies, school records, birth certificates, official government correspondence, or other government records. In the event of a name change, applicants should provide the court records or other government documents documenting that name change.

An applicant who resided in a Disproportionately Impacted Area but was homeless for some or all of the relevant time period may provide a signed Homeless Status Verification form provided by the Illinois Secretary of State (available here: _publications/dsd_a230.pdf) to show they resided in a Disproportionately Impacted Area during that period of time.

Applicants, including veterans or active duty military personnel, may use any residence listed on tax forms submitted to the State of Illinois as their primary residence as evidence of their residence in a Disproportionately Impacted Area. Veterans or active duty military personnel will not be disadvantaged by time spent away from their primary residence due to their military service.

To demonstrate evidence as a Social Equity Applicant through employment, applicants must submit something more than a mere statement of qualification. Applicants should submit sufficient records to establish the employees as meeting social equity criteria and to establish their employment with applicant. Examples of such records include, but are not limited to, W-2 and/or W-4 forms, pay stubs, New Hire Reporting Forms submitted to the Illinois Department of Employment Security, payroll records, residency records, income tax forms, court records and disposition papers, utility bills, insurance forms, bank statements, pension payments, records from public assistance agencies, court records, government records and school records.

"Full-time employee" means an individual for whom a W-2 is issued by the applicant and is employed for a basic wage for at least 35 hours each week. "Basic Wage" means compensation for employment that is no less than the legal minimum wage of the jurisdiction in which the person is employed. Salary shall consist of all basic wage compensation not including overtime pay, bonus pay, stock options, awards or any other equity-based incentive, unreimbursed employee expenses or piecemeal rate of pay, or any form of deferred compensation. 10.

A record of the arrest, conviction, or adjudication from the responsible legal authority. One example of a document that may demonstrate a Principal Officer was arrested for, convicted of, or adjudicated delinquent for an offense that is eligible for expungement pursuant to the Act is a "disposition paper" from the court in the applicable jurisdiction. Applicants that have had their cannabis arrest expunged in the past may: (1) provide a court record showing that an expungement was granted, (2) apply to the circuit court that granted the expungement to unseal the records of the arrest and provide a copy of those records to the Department, or (3) provide any other records that serve as evidence of the prior arrest, conviction, or adjudication. Affidavits from the accused will not be considered sufficient without additional documentation.

Offenses identified in Sections 4 and 5 of the Illinois Cannabis Control Act (720 ILCS 550) that were classified as Class 4 felonies or misdemeanors at the time of the offense are eligible for expungement. None of these crimes are expungable if the offense was associated with a violent crime or a penalty enhancement for selling to a person under the age of 18 if the seller was over the age of 18. Applicants should review whether their offense was charged as a Class 4 felony or any level misdemeanor to verify their eligibility for expungement

3a8082e126